Where will the next generation of stroke treatments come from?

PLoS Medicine

Volumn 7, Issue 3, 2010, Pages 1-5

  Howells, D W ^a   Donnan, G A ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 7; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMATINIB; INCRETIN; NOTCH3 RECEPTOR; OXYGEN; THROMBIN INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ANGIOPLASTY; ARTICLE; BLOOD CLOT LYSIS; BRAIN DECOMPRESSION; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; BRAIN SURGERY; CADASIL; CAROTID ENDARTERECTOMY; CIGARETTE SMOKING; CLINICAL TRIAL; DIABETES MELLITUS; DRUG TARGETING; DYSLIPIDEMIA; EMBOLECTOMY; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; HEART ATRIUM FIBRILLATION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; MEDICAL RESEARCH; NERVE CELL PLASTICITY; NEUROPROTECTION; OCCLUSIVE CEREBROVASCULAR DISEASE; PATHOPHYSIOLOGY; POPULATION GENETICS; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STROKE; THROMBECTOMY;

HUMANS; STROKE;

EID: 77950671279     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1000224     Document Type: Article

References (74)

1. Leary MC, Saver JL (2003) Annual incidence of first silent stroke in the United States: a preliminary estimate. Cerebrovasc Dis 16: 280-285.
2. Donnan GA, Fisher M, Macleod M, Davis SM (2008) Stroke. Lancet 371: 1612-1623.
3. Mergenthaler P, Dirnagl U, Meisel A (2004) Pathophysiology of stroke: lessons from animal models. Metab Brain Dis 19: 151-167.
4. Donnan G, Baron J, Davis S, Sharp F (2006) The Ischaemic Penumbra: history, current status and implications for therapy. New York: Informa Health Care Inc.
5. PROGRESS Collaborative Group (2001) Randomised trial of a perindopril-based bloodpressure- lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358: 1033-1041.
6. Kizer JR, Dahlof B, Kjeldsen SE, Julius S, Beevers G, et al. (2005) Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. Hypertension 45: 46-52.
7. Amarenco P, Bogousslavsky J, Callahan A, 3rd, Goldstein LB, Hennerici M, et al. (2006) Highdose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355: 549-559.
8. Granger CB, White HD, Bates ER, Ohman EM, Califf RM (1994) A pooled analysis of coronary arterial patency and left ventricular function after intravenous thrombolysis for acute myocardial infarction. Am J Cardiol 74: 1220-1228.
9. Vahedi K, Hofmeijer J, Juettler E, Vicaut E, George B, et al. (2007) Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials. Lancet Neurol 6: 215-222.
10. Langhorne P, Williams BO, Gilchrist W, Howie K (1993) Do stroke units save lives? Lancet 342: 395-398.
11. Feigin VL, Lawes CM, Bennett DA, Anderson CS (2003) Stroke epidemiology: a review of population- based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol 2: 43-53.
12. Bonita R, Beaglehole R (1989) Increased treatment of hypertension does not explain the decline in stroke mortality in the United States, 1970-1980. Hypertension 13: I69-73.
13. Bejot Y, Ben Salem D, Osseby GV, Couvreur G, Durier J, et al. (2009) Epidemiology of ischemic stroke from atrial fibrillation in Dijon, France, from 1985 to 2006. Neurology 72: 346-353.
14. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, et al. (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361: 1139-1151.
15. Kwon HM, Kim BJ, Park JH, Ryu WS, Kim CK, et al. (2009) Significant association of metabolic syndrome with silent brain infarction in elderly people. J Neurol.
16. Lovshin JA, Drucker DJ (2009) Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 5: 262-269.
17. Diener HC (2006) Secondary stroke prevention with antiplatelet drugs: have we reached the ceiling? Int J Stroke 1: 4-8.
18. Hoksbergen AW, Majoie CB, Hulsmans FJ, Legemate DA (2003) Assessment of the collateral function of the circle of Willis: three-dimensional time-of-flight MR angiography compared with transcranial color-coded duplex sonography. AJNR Am J Neuroradiol 24: 456-462.
19. Miteff F, Levi CR, Bateman GA, Spratt N, McElduff P, et al. (2009) The independent predictive utility of computed tomography angiographic collateral status in acute ischaemic stroke. Brain 132: 2231-2238.
20. Biswas A, Tiwari AK, Ranjan R, Meena A, Akhter MS, et al. (2009) Prothrombotic polymorphisms, mutations, and their association with pediatric non-cardioembolic stroke in Asian- Indian patients. Ann Hematol 88: 473-478.
21. Adamski MG, Turaj W, Slowik A, Wloch-Kopec D, Wolkow P, et al. (2009) A-G-4G haplotype of PAI-1 gene polymorphisms -844 G/A, HindIII G/C, and -675 4G/5G is associated with increased risk of ischemic stroke caused by small vessel disease. Acta Neurol Scand 120: 94-100.
22. Gilligan AK, Thrift AG, Sturm JW, Dewey HM, Macdonell RA, et al. (2005) Stroke Units, Tissue Plasminogen Activator, Aspirin and Neuroprotection: Which Stroke Intervention Could Provide the Greatest Community Benefit? Cerebrovasc Dis 20: 239-244.
23. Dawson TM, Dawson VL (2006) Taming the clot-buster tPA. Nat Med 12: 993-994.
24. Bluhmki E, Chamorro A, Davalos A, Machnig T, Sauce C, et al. (2009) Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol 8: 1095-1102.
25. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, et al. (2008) Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 359: 1317-1329.
26. Su EJ, Fredriksson L, Geyer M, Folestad E, Cale J, et al. (2008) Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med 14: 731-737.
27. Ladenvall C, Gils A, Jood K, Blomstrand C, Declerck PJ, et al. (2007) Thrombin activatable fibrinolysis inhibitor activation peptide shows association with all major subtypes of ischemic stroke and with TAFI gene variation. Arterioscler Thromb Vasc Biol 27: 955-962.
28. Brouns R, Heylen E, Sheorajpanday R, Willemse JL, Kunnen J, et al. (2009) Carboxypeptidase U (TAFIa) decreases the efficacy of thrombolytic therapy in ischemic stroke patients. Clin Neurol Neurosurg 111: 165-170.
29. Semeraro F, Ammollo CT, Semeraro N, Colucci M (2009) Tissue factor-expressing monocytes inhibit fibrinolysis through a TAFI-mediated mechanism, and make clots resistant to heparins. Haematologica 94: 819-826.
30. Bajzar L, Nesheim ME, Tracy PB (1996) The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 88: 2093-2100.
31. Bird E, Tamura J, Bostwick JS, Steinbacher TE, Stewart A, et al. (2007) Is exogenous tissue plasminogen activator necessary for antithrombotic efficacy of an inhibitor of thrombin activatable fibrinolysis inhibitor (TAFI) in rats? Thromb Res 120: 549-558.
32. Smith WS, Sung G, Starkman S, Saver JL, Kidwell CS, et al. (2005) Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke 36: 1432-1438.
33. Bose A, Henkes H, Alfke K, Reith W, Mayer TE, et al. (2008) The Penumbra System: a mechanical device for the treatment of acute stroke due to thromboembolism. AJNR Am J Neuroradiol 29: 1409-1413.
34. Macleod MR, Fisher M, O'Collins V, Sena ES, Dirnagl U, et al. (2009) Good laboratory practice: preventing introduction of bias at the bench. Stroke 40: e50-52.
35. Sena E, van der Worp HB, Howells D, Macleod M (2007) How can we improve the pre-clinical development of drugs for stroke? Trends Neurosci 30: 433-439.
36. STAIR (1999) Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30: 2752-2758.
37. van der Worp HB, Sena ES, Donnan GA, Howells DW, Macleod MR (2007) Hypothermia in animal models of acute ischaemic stroke: a systematic review and meta-analysis. Brain 130: 3063-3074.
38. Bernard S (2006) Therapeutic hypothermia after cardiac arrest: now a standard of care. Crit Care Med 34: 923-924.
39. Salussolia CL, Nalwalk JW, Hough LB (2007) Improgan-induced hypothermia: a role for cannabinoid receptors in improgan-induced changes in nociceptive threshold and body temperature. Brain Res 1152: 42-48.
40. Aslami H, Schultz MJ, Juffermans NP (2009) Potential applications of hydrogen sulfide-induced suspended animation. Curr Med Chem 16: 1295-1303.
41. Sessler DI (2009) Defeating normal thermoregulatory defenses: induction of therapeutic hypothermia. Stroke 40: e614-621.
42. Henninger N, Bouley J, Nelligan JM, Sicard KM, Fisher M (2007) Normobaric hyperoxia delays perfusion/diffusion mismatch evolution, reduces infarct volume, and differentially affects neuronal cell death pathways after suture middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab 27: 1632-1642.
43. Singhal AB, Benner T, Roccatagliata L, Koroshetz WJ, Schaefer PW, et al. (2005) A pilot study of normobaric oxygen therapy in acute ischemic stroke. Stroke 36: 797-802.
44. Holtmaat A, Svoboda K (2009) Experiencedependent structural synaptic plasticity in the mammalian brain. Nat Rev Neurosci 10: 647-658.
45. Curtis MA, Eriksson PS, Faull RL (2007) Progenitor cells and adult neurogenesis in neurodegenerative diseases and injuries of the basal ganglia. Clin Exp Pharmacol Physiol 34: 528-532.
46. Kuhlmann T, Miron V, Cuo Q, Wegner C, Antel J, et al. (2008) Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis. Brain 131: 1749-1758.
47. Johansson BB (2000) Brain plasticity and stroke rehabilitation. The Willis lecture. Stroke 31: 223-230.
48. Minnerup J, Heidrich J, Wellmann J, Rogalewski A, Schneider A, et al. (2008) Metaanalysis of the efficacy of granulocyte-colony stimulating factor in animal models of focal cerebral ischemia. Stroke 39: 1855-1861.
49. Daadi MM, Maag AL, Steinberg GK (2008) Adherent self-renewable human embryonic stem cell-derived neural stem cell line: functional engraftment in experimental stroke model. PLoS One 3: e1644.
50. Ott HC, Matthiesen TS, Goh SK, Black LD, Kren SM, et al. (2008) Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart. Nat Med 14: 213-221.
51. Dirnagl U, Schwab JM (2009) Brain-immune interactions in acute and chronic brain disorders. Neuroscience 158: 969-971.
52. Batchelor PE, Liberatore GT, Wong JY, Porritt MJ, Frerichs F, et al. (1999) Activated macrophages and microglia induce dopaminergic sprouting in the injured striatum and express brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor. J Neurosci 19: 1708-1716.
53. Lo EH (2008) A new penumbra: transitioning from injury into repair after stroke. Nat Med 14: 497-500.
54. Whisnant J (1997) Modeling of risk factors for ischemic stroke. The Willis Lecture. Stroke 28: 1840-1844.
55. Louvi A, Arboleda-Velasquez JF, Artavanis-Tsakonas S (2006) CADASIL: a critical look at a Notch disease. Dev Neurosci 28: 5-12.
56. Bilguvar K, Yasuno K, Niemela M, Ruigrok YM, von Und Zu Fraunberg M, et al. (2008) Susceptibility loci for intracranial aneurysm in European and Japanese populations. Nat Genet 40: 1472-1477.
57. Gschwendtner A, Bevan S, Cole JW, Plourde A, Matarin M, et al. (2009) Sequence variants on chromosome 9p21.3 confer risk for atherosclerotic stroke. Ann Neurol 65: 531-539.
58. (1995) Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 333: 1581-1587.
59. (1997) The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet 349: 1569-1581.
60. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, et al. (2005) Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 352: 777-785.
61. Mendelow AD, Gregson BA, Fernandes HM, Murray GD, Teasdale GM, et al. (2005) Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet 365: 387-397.
62. Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, et al. (2005) The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 36: 66-73.
63. Alexandrov AV, Molina CA, Grotta JC, Garami Z, Ford SR, et al. (2004) Ultrasoundenhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med 351: 2170-2178.
64. (2006) Glyceryl trinitrate vs. control, and continuing vs. stopping temporarily prior antihypertensive therapy, in acute stroke: rationale and design of the Efficacy of Nitric Oxide in Stroke (ENOS) trial (ISRCTN99414122). Int J Stroke 1: 245-249.
65. Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, et al. (2006) NXY-059 for acute ischemic stroke. N Engl J Med 354: 588-600.
66. (1978) A randomized trial of aspirin and sulfinpyrazone in threatened stroke. The Canadian Cooperative Study Group. N Engl J Med 299: 53-59.
67. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, et al. (1996) European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 143: 1-13.
68. CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348: 1329-1339.
69. (1993) Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 342: 1255-1262.
70. (1991) Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. North American Symptomatic Carotid Endarterectomy TrialCollaborators. NEngl JMed 325: 445-453.
71. (1991) MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis. European Carotid Surgery Trialists' Collaborative Group. Lancet 337: 1235-1243.
72. (2001) Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358: 1033-1041.
73. Amarenco P, Bogousslavsky J, Callahan A, Goldstein LB, Hennerici M, et al. (2006) Highdose atorvastatin after stroke or transient ischemic attack. New England Journal of Medicine 355: 549-559.
74. Yadav JS, Wholey MH, Kuntz RE, Fayad P, Katzen BT, et al. (2004) Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med 351: 1493-1501.